Head-to-head · WeighScore
Medical Health Institute vs NexLife
The verdict
NexLife takes it — 68.7/100 to 53.3/100.
NexLife grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NexLife is a LegitScript-certified telehealth platform offering compounded semaglutide (from $145/mo) and compounded tirzepatide (from $186/mo).
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Medical Health Institute | NexLife |
|---|---|---|
| WeighScore | 53.3/100 | 68.7/100 |
| Grade | C | C |
| Scorecard rank | #469 | #139 |
| Semaglutide | Not disclosed | $165/mo (compounded) |
| Tirzepatide | Not disclosed | $215/mo (compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #469 · C
Strengths
- Operating entity disclosed: Medical Health Institute, LLC, with full Pinecrest, FL address and phone
- Named medical director (Amy Wecker, MD) plus four more named clinicians on the about page
- Three care pathways with starting-price anchors: $99 TRT / $129 peptides / $149 weight-loss
- LegitScript Certified with a footer verification link
- HIPAA compliance claimed
Where it loses points
- GLP-1 medication options (semaglutide vs tirzepatide; compounded vs brand) not shown — gated behind the intake funnel
- Pharmacy partner not named — only generic 'FDA-regulated facilities' language
- State availability not disclosed
- Several subpages (/weight-loss, /pricing, /products, /faq) returned server errors during verification
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #139 · C
Strengths
- LegitScript certified platform
- Works exclusively with LegitScript-certified, NABP-accredited pharmacies — strongest pharmacy trust signal in the dataset
- Both semaglutide and tirzepatide at competitive pricing
- Semaglutide from $145/mo on the 12-month plan ($165/mo month-to-month) - among the lowest in the dataset
Where it loses points
- State availability not publicly disclosed
- Compounded only — no brand-name options
- Also covers hormone optimization and longevity
- Lowest advertised rates ($145 sema / $186 tirz) require a 12-month plan commitment
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.